Fundraising Fox

Click Therapeutics

New York, US · Founded 2012 · Delaware corporation · 10 known investors

Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Click Therapeutics was founded in 2012 by David B. Klein.

DB
David B. KleinFounder and CEO
RSRandall Stanicky
Randall StanickyExecutive
DK
David KleinNamed on SEC filing

Board

AZ
Alex ZissonBoard directorManaging Director at H.I.G. HealthBridge Partners
LSLee Shapiro
Lee ShapiroinBoard Member2021–2025Partner at 7wire Ventures
CDCris De Luca
Cris De Lucain𝕏Board MemberPartner, Digital at Sanofi Ventures
MF
Maria ForeroBoard director
DF
David FriedmanBoard director
LC
Lezrene CunninghamBoard director
JB
Jeffrey BerkowitzBoard director
MM
Muzammil MansuriBoard director
NS
Nicholas SchorkBoard director

Investors · 10

Accelmed PartnersMiami
H.I.G. CapitalMiami
H.I.G. HealthBridge PartnersMiami · $5M – $40M
Health Catalyst CapitalNew York
Hikma VenturesLondon · $5M
Sanofi VenturesCambridge · $5Mvia Cris De Luca · board
Supernode VenturesNew York · $500K – $1.3M
7wire VenturesreportedChicago · $100K – $5Mvia Lee Shapiro · board
Boehringer Ingelheim Venture FundreportedIngelheim am Rhein · $16.2M

Also in the syndicate · 1

Boehringer Ingelheim

Funding

SEC filings, press & company announcements

$236.7M disclosed across 11 rounds · 2014–2026

  • $50MraisedApr 2026 · 2 sources
    Source ↗
  • $50MSeries DApr 2026 · 3 sources

    Boehringer Ingelheim

    Source ↗
▶$48.6MraisedApr 2025 · 3 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Lee ShapiroDirector
  • Anthony CostelloDirector
  • Maria ForeroDirector
  • Lezrene CunninghamDirector
  • Alex ZissonDirector
  • Cris De LucaDirector
  • Jeffrey BerkowitzDirector
  • David B. KleinExecutive Officer, Director
  • David FriedmanDirector
  • Muzammil MansuriDirector
  • Randall StanickyExecutive Officer
Offering amount
$48.6M
Amount sold
$48.6M
First sale
Mar 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.3MraisedNov 2024 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Maria ForeroDirector
  • Alex ZissonDirector
  • David FriedmanDirector
  • Randall StanickyExecutive Officer
  • David B. KleinExecutive Officer, Director
  • Lezrene CunninghamDirector
  • Jeffrey BerkowitzDirector
  • Lee ShapiroDirector
  • Cris De LucaDirector
  • Muzammil MansuriDirector
Offering amount
$8.3M
Amount sold
$8.3M
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedNov 2024 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Randall StanickyExecutive Officer
  • Maria ForeroDirector
  • Cris De LucaDirector
  • Lee ShapiroDirector
  • David KleinExecutive Officer, Director
  • Jeffrey BerkowitzDirector
  • Alex ZissonDirector
  • Muzammil MansuriDirector
  • Lezrene CunninghamDirector
Offering amount
$3M
Amount sold
$3M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$52.1MraisedNov 2021 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Lee ShapiroDirector
  • David KleinExecutive Officer, Director
  • Jeff BerkowitzDirector
  • Cris De LucaDirector
  • Muzammil MansuriDirector
  • Uri GeigerDirector
  • Alex ZissonDirector
  • Randall StanickyExecutive Officer
Offering amount
$52.1M
Amount sold
$52.1M
First sale
Oct 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17.3MraisedJun 2018 · 50 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John SadowskiDirector
  • Nicholas SchorkDirector
  • Ted SilverExecutive Officer
  • David KleinExecutive Officer, Director
Offering amount
$19.3M
Amount sold
$17.3M
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.7MraisedApr 2017 · 11 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Nicholas SchorkDirector
  • David KleinExecutive Officer, Director
  • Emile WestergaardDirector
  • Victor GaoDirector
Offering amount
$5M
Amount sold
$3.7M
First sale
Apr 2017
Incorporated
Corporation, New York
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$805KraisedApr 2016 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Nicholas SchorkDirector
  • Victor GaoDirector
  • David KleinExecutive Officer, Director
  • Emile WestergaardDirector
Offering amount
$1.5M
Amount sold
$805K
Minimum investment
$25K
First sale
Apr 2016
Incorporated
Corporation, New York, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedAug 2015 · 18 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Nicholas SchorkDirector
  • David KleinExecutive Officer, Director
  • Victor GaoDirector
  • Emile WestergaardDirector
Offering amount
$3M
Amount sold
$1.8M
Sales commissions
$63.5K
Placement agents
Jonathan Sadowsky
First sale
Jul 2015
Incorporated
Corporation, New York, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$224.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Click Therapeutics raises $50M and more funding news | MobiHealthNewsmobihealthnews.com · Apr 2026Click Therapeutics raises Series D funding for app-based treatments - Crain's New York Businesscrainsnewyork.com · Apr 2026[Updated] Click Therapeutics Raises $50M, Reportedly Cuts 27% of Workforce - Behavioral Health Businessbhbusiness.com · Apr 2026Click Therapeutics Closes $50M Series D Funding from Boehringer Ingelheimfinsmes.com · Apr 2026Click Therapeutics Raises $50M Series D for Schizophrenia DTx - TAMradar Funding Rounds Signalstamradar.com · Apr 2026Boehringer and Click Announce CT-155 Funding and Investment | Boehringer Ingelheim USboehringer-ingelheim.com · Apr 2026

Frequently asked questions

What does Click Therapeutics do?
Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.
Who founded Click Therapeutics?
Click Therapeutics was founded by David B. Klein in 2012.
Who are Click Therapeutics's investors?
Click Therapeutics's investors include Accelmed Partners, H.I.G. Capital, H.I.G. HealthBridge Partners, Health Catalyst Capital, Hikma Ventures, Sanofi Ventures, Supernode Ventures, 7wire Ventures and 1 more.
How much funding has Click Therapeutics raised?
Click Therapeutics has disclosed $236.7M raised across 11 rounds.
Where is Click Therapeutics headquartered?
Click Therapeutics is headquartered in New York, US.